Andexanet alfa specifically binds and sequesters factor Xa inhibitors. A study investigated the efficacy and safety of andexanet alfa in patients on edoxaban with acute major bleeding.

AHA 2021 In this video, prof. Marcus explains the methodology of n-of-1 trials in the I-STOP-AF trial and summarizes the findings.

AHA 2021 In the I-STOP AF trial, n-of-1 trials with individual triggers did not result in a change in AF-related quality of life compared to monitoring only.

AHA 2021 The Fitbit Heart study examined whether a novel photoplethysmography (PPG) software algorithm for Fitbit wearables can identify atrial fibrillation in a large population.

AHA 2021 A novel software algorithm with input of irregular heart rhythm detection by Fitbit wearables had a positive predictive value of 98% for undiagnosed atrial fibrillation (AF).

AHA 2021 The majority of cognitive outcome tests was not different between AF patients treated with dabigatran or warfarin after two years in the GIRAF trial.

Using data of Medicare claims, this study investigated whether frailty affected the effect of dabigatran, rivaroxaban, or apixaban vs. warfarin on adverse outcomes in AF patients ≥65 years.

This study found inappropriate DOAC prescriptions in 16.9% of hospitalized patients with AF, with underdosing being more common than overdosing. Moreover, this study identified determinants of DOAC under- and overdosing.

ESC 2021 In the ENVISAGE-TAVI AF trial, the effect of edoxaban on net adverse clinical events (NACE) was compared to VKAs in elderly patients with AF who underwent TAVI.

ESC 2021 The LOOP study showed that continuous heart rhythm monitoring using an implantable loop recorder and initiation of OAC if AF was detected, did not prevent stroke in patients at high risk compared to standard care.

ESC 2021 Non-inferiority was met for edoxaban when compared with VKA for net adverse clinical events (NACE) in patients with AF after TAVI, but major bleeding was higher in those receiving edoxaban.

ESC HF 2021 This analysis of the VICTORIA trial showed that the beneficial effects of vericiguat were unaffected by AF status at baseline.